JUMP REPORT
| Avg Daily Volume: 3,228,388 Market Cap: 12.53B Sector: Technology Short Interest: 7.83 |
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .03/share REV: 239.8/M
___________________________________________________________
LAST QTR: EPS: .04/share ACTUAL: .01/share (MISS)
____________________________________________________________
NEXT QTR: EPS: .05/share REV: 260.4/M
______________________________________________________
FULL YR: EPS: .16/share REV: 950.9/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
______________________________________________________
BEAT/MISS RECORD: 40% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 0, -16.5, -4.29
EXPECTED JUMP MOVE: 12%
Links To Latest News and Headlines
The stay-at-home stocks quickly came back into favor on news of a setback with Johnson & Johnson’s single-dose COVID-19 vaccine.
A setback for a major coronavirus vaccine maker is driving investors to seek shelter in stocks that have held up well during the pandemic.
In this video I’m going to discuss why DocuSign (NASDAQ: DOCU) will continue to see success even after the pandemic is over because let’s face it, e-signature and digital contracts are the future. When most people think DocuSign, they just think about e-signature. Well, the CEO says the signing business is as big as $25 billion, and DocuSign has the largest market share at close to 900,000 customers.
In the latest trading session, DocuSign (DOCU) closed at $212.97, marking a +0.33% move from the previous day.
DocuSign Inc (NASDAQ: DOCU) is an industry-leading brand in the contract lifecycle management and eSignature market, and the market is an underappreciated one, according to BofA Securities. The DocuSign Analyst: Brad Sills reinstated coverage of DocuSign with a Buy rating and $250 price target. The DocuSign Takeaways: “DocuSign screens well in our 4M framework for software investing,” Sills said in a Thursday note. Contracting workflow and eSignatures represent a combined opportunity of $24 billion, the analyst said. DocuSign’s competitive moat stems from a large installed base of over 822,000 customers, a distribution channel of 3,000-plus sales and marketing personnel and its eSignature and agreement software, he said. Sills said he expects DocuSign to “continue benefitting from a strong adoption cycle, stemming from demand for a cloud based solution which reduces contract execution cycles time from weeks to less than a day.” Given the large market DocuSign addresses and its competitive positioning, “we believe a long runway exists for 25%+ revenue growth,” the analyst said. DOCU Price Action: Shares of DocuSign were trading 3.27% higher to $212.44 at the time of publication Thursday. Latest Ratings for DOCU DateFirmActionFromTo Apr 2021B of A SecuritiesReinstatesBuy Mar 2021Daiwa CapitalInitiates Coverage OnBuy Mar 2021Wells FargoMaintainsEqual-Weight View More Analyst Ratings for DOCU View the Latest Analyst Ratings See more from BenzingaClick here for options trades from BenzingaWhy Did BofA Upgrade 3 Triple-net Lease REITs?How Waste Management’s Profitability And Competitive Positioning Caught This Analyst’s Eye© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
StockJumpers analysis and trade plans are uploaded generally 1 HOUR (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is striped down to only what it needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.